Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Isofol Medical AB ( (SE:ISOFOL) ).
Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, intended as a new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, will assess the benefit/risk profile of escalating doses and compare efficacy parameters, marking a significant step towards market readiness and potentially offering improved treatment options for patients with advanced cancers.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company’s primary drug candidate, arfolitixorin, aims to enhance the efficacy of first-line standard treatments for various solid tumors, with current studies targeting colorectal cancer, the third most common cancer globally.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
Find detailed analytics on ISOFOL stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money